Skip to main content
SpringerLink
Log in

Tumor-targeting, Systemically Delivered Antisense HER-2 Chemosensitizes Human Breast Cancer Xenografts Irrespective of HER-2 Levels

  • Original Articles
  • Published:
Molecular Medicine Aims and scope Submit manuscript

Abstract

Background

The failure to respond to chemotherapy is a major obstacle in the successful treatment of breast cancer. We have previously shown that anti-HER-2 antisense oligonucleotide (AS HER-2 ODN) treatment was able to sensitize breast cancer cells to various chemotherapeutic agents in vitro irrespective of their HER-2 status, indicating that the use of AS HER-2 ODN therapy for breast cancer is not limited to tumors overexpressing the protein. One of the main drawbacks to the use of antisense therapy in the clinical setting is the lack of an efficient, tumor-targeting, systemic delivery method. We have developed a tumor-specific, ligand-targeting, cationic liposome delivery system designed for systemic gene therapy of cancer. In this study we employ this ligand-liposome strategy to enhance the delivery of the AS Her-2 ODN to breast cancer cells, including those that do not overexpress HER-2, in vitro and in vivo.

Materials and Methods

A cationic liposome complex that includes folate as the targeting ligand was designed and optimized for more efficient delivery of AS HER-2 ODN to breast tumors cells in vitro, and more significantly, for systemic delivery with tumor-specific targeting in vivo. Human breast cancer cell line MDA-MB-435, which does not overexpress HER-2, was used to compare the degree of chemosensitization to the taxanes of AS HER-2 ODN delivered via the optimized folateliposome versus commercial Lipofectin. MDA-MB-435 xenograft tumors were also used to evaluate the anti-tumor effect of the combination of systemically delivered folate-liposome-AS HER-2 ODN and docetaxel (Taxotere).

Results

The optimized folate-liposome-AS HER-2 ODN complex significantly increases the response of breast tumor cell lines to conventional chemotherapeutic agents in vitro as compared to AS HER-2 delivered via an unliganded commercially available reagent, Lipofectin. In vivo, the folate-liposome-AS HER-2 ODN complex has prolonged stability in blood and increased uptake in tumors. More significantly, the combination of intravenously administered ligand-liposome-AS HER-2 ODN and docetaxel resulted in a marked inhibition of xenograft growth in an aggressive breast cancer model that does not overexpress HER-2, even after treatment ended.

Conclusions

Although there are other reports of liposomal delivery of AS ODNs, this is the first report of in vivo efficacy against human cancer cells using a tumor-targeting liposome delivery system for systemic AS therapy. Moreover, the increased stability in circulation and anti-tumor efficacy observed were obtained without the need for continuous intravenous infusion. HER-2 is an integral component within a network of cell growth pathways that can affect many different types of tumors where HER-2 may be a contributing factor, such as ovarian, esophageal, and GI malignancies including colon and pancreatic cancers. Therefore, the effectiveness of this therapy with xenograft tumors that do not overexpress HER-2 has the potential to expand the clinical usefulness of this efficacious form of therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3A-E
Fig. 4
Fig. 5
Fig. 6

Similar content being viewed by others

References

  1. Klapper LN, Kirschbaum MH, Sela M, Yarden Y. (2000) Biochemical and clinical implications of the ErbB/HER signaling network of growth factor receptors. Adv. Cancer Res. 77: 25–79.

    Article  CAS  PubMed  Google Scholar 

  2. Stancovski I, Sela M, Yarden Y. (1994) Molecular and clinical aspects of the Neu/ErbB- 2 receptor tyrosine kinase. Cancer-Treat. Res. 71: 161–191.

    Article  CAS  PubMed  Google Scholar 

  3. Slamon DJ, Godolphin W, Jones LA, et al. (1989) Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244: 707–712.

    Article  CAS  PubMed  Google Scholar 

  4. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. (1987) Human breast cancer: correlation of relapse and survival with amplification of the Her-2/neu oncogene. Science 235: 177–182.

    Article  CAS  PubMed  Google Scholar 

  5. Pegram MD, Finn RS, Arzoo K, Beryt M, Pietras RJ, Slamon DJ. (1997) The effect of HER-2/neu overexpression on chemotherapeutic drug sensitivity in human breast and ovarian cancer cells. Oncogene 15: 537–547.

    Article  CAS  PubMed  Google Scholar 

  6. Pegram M, Hsu S, Lewis G, et al. (1999) Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers. Oncogene 18: 2241–2251.

    Article  CAS  PubMed  Google Scholar 

  7. Burris HA III. (2001) Docetaxel (Taxotere) plus trastuzumab (Herceptin) in breast cancer. Semin. Oncol. 28: 38–44.

    Article  CAS  PubMed  Google Scholar 

  8. Ring CJ, Blouin P, Martin LA, Hurst HC, Lemoine NR. (1997) Use of transcriptional regulatory elements of the MUC1 and ERBB2 genes to drive tumour-selective expression of a prodrug activating enzyme. Gene Ther. 4: 1045–1052.

    Article  CAS  PubMed  Google Scholar 

  9. Ueno NT, Yu D, Hung MC. (2001) E1A: tumor suppressor or oncogene? Preclinical and clinical investigations of E1A gene therapy. Breast Cancer 8: 285–293.

    Article  CAS  PubMed  Google Scholar 

  10. Rait AS, Pirollo KF, Rait V, Krygier JE, Xiang L, Chang EH. (2001) Inhibitory effects of the combination of HER-2 antisense oligonucleotide and chemotherapeutic agents used for the treatment of human breast cancer. Cancer Gene Ther. 8: 728–739.

    Article  CAS  PubMed  Google Scholar 

  11. Xu L, Pirollo KF, Rait A, Murray A, Chang EH. (1999) Systemic p53 gene therapy in combination with radiation results in human tumor regression. Tumor Targeting 4: 92–104.

    CAS  Google Scholar 

  12. Xu L, Pirollo KF, Tang WH, Rait A, Chang EH. (1999) Transferrin-liposome-mediated systemic p53 gene therapy in combination with radiation results in regression of human head and neck cancer xenografts. Human Gene Ther. 10: 2941–2952.

    Article  CAS  Google Scholar 

  13. Xu L, Pirollo KF, Chang EH. (1997) Transferrin-liposome-me-diated p53 sensitization of squamous cell carcinoma of the head and neck to radiation in vitro. Human Gene Ther. 8: 467–475.

    Article  CAS  Google Scholar 

  14. Xu L, Pirollo KF, Chang EH. (2001) Tumor-targeted p53 gene therapy enhances the efficacy of conventional chemo/radio-therapy. J. Control Release 6: 115–128.

    Article  Google Scholar 

  15. Sambrook J, Fritsch EF, Maniatis T. (1989) Molecular Cloning: A Laboratory Manual, 2nd ed. Cold Spring Harbor Laboratory Press, Plainview, NY, USA.

    Google Scholar 

  16. Rait A, Krygier JE, Pirollo KF, Chang EH. (1999) Sensitization of breast cancer cells to taxol by antisense HER-2 oligonucleotides. Antisense Nucleic Acid Drug Dev. 9: 403–408.

    Article  CAS  Google Scholar 

  17. Crown JP. (2001) The platinum agents: a role in breast cancer treatment? Semin. Oncol. 28: 28–37.

    Article  CAS  PubMed  Google Scholar 

  18. Nabholtz JM, Tonkin K, Smylie M, Au HJ, Lindsay MA, Mackey J. (2000) Chemotherapy of breast cancer: are the taxanes going to change the natural history of breast cancer? Expert Opin. Pharmacother. 1: 187–206.

    Article  CAS  PubMed  Google Scholar 

  19. O’Leary J VMWCMF. (1998) Taxanes in adjuvant and neoad-juvant therapies for breast cancer. Oncology 12: 23–27.

    PubMed  Google Scholar 

  20. Agrawal S, Zhao Q. (1998) Mixed backbone oligonucleotides: improvement in oligonucleotide-induced toxicity in vivo. Antisense Nucleic Acid Drug Dev. 8: 135–139.

    Article  CAS  PubMed  Google Scholar 

  21. Glover J, Leeds JM, Mant T, et al. (1997) Phase I safety and pharmacokinetic profile of an intercellular adhesion molecule-1 antisense oligodeoxynucleotide (ISIS 2302). J. Pharmacol. Exp. Ther. 282: 1173–1180.

    PubMed  CAS  Google Scholar 

  22. Rait A, Uhlmann E, Peyman A, Will DW, Chang EH. (2000) Inhibition of Ras p21 synthesis by antisense undecamers with uniform and specifically arranged phosphorothioate linkages. Anticancer Drugs 11: 181–191.

    Article  CAS  PubMed  Google Scholar 

  23. Zamecnik PC, Stephenson ML. (1978) Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide. Proc. Natl. Acad. Sci. U.S.A. 75: 280–284.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Stephenson ML, Zamecnik PC. (1978) Inhibition of Rous sarcoma viral RNA translation by a specific oligodeoxyribonucleotide. Proc. Natl. Acad. Sci. U.S.A. 75: 285–288.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Crooke ST. (1998) Vitravene-another piece in the mosaic. Antisense Nucleic Acid Drug Dev. 8: vii–viii.

    Article  CAS  PubMed  Google Scholar 

  26. Akhtar S, Hughes MD, Khan A, et al. (2000) The delivery of antisense therapeutics. Adv. Drug Deliv. Rev. 44: 3–21.

    Article  CAS  PubMed  Google Scholar 

  27. Tamm I, Dorken B, Hartmann G. (2001) Antisense therapy in oncology: new hope for an old idea? Lancet 358: 489–497.

    Article  CAS  PubMed  Google Scholar 

  28. Akhtar S. (1998) Antisense technology: selection and delivery of optimally acting antisense oligonucleotides. J. Drug Target. 5: 225–234.

    Article  CAS  PubMed  Google Scholar 

  29. Juliano RL, Alahari S, Yoo H, Kole R, Cho M. (1999) Antisense pharmacodynamics: critical issues in the transport and delivery of antisense oligonucleotides. Pharm. Res. 16: 494–502.

    Article  CAS  PubMed  Google Scholar 

  30. Yuen AR, Halsey J, Fisher GA, et al. (1999) Phase I study of an antisense oligonucleotide to protein kinase C-alpha (ISIS 3521/CGP 64128A) in patients with cancer. Clin. Cancer Res. 5: 3357–3363.

    PubMed  CAS  Google Scholar 

  31. Advani R, Fisher G, Lum B, et al. (2000) Coagulation and complement effects of an antisense phosphorothioate oligonucleotide targeting protein kinase C-alpha (ISIS 3521) are schedule and dose dependent. Proc. Am. Soc. Clin. Oncol. 17: 3586–3595.

    Google Scholar 

  32. Nemunaitis J, Holmlund JT, Kraynak M, et al. (1999) Phase I evaluation of ISIS 3521, an antisense oligodeoxynucleotide to protein kinase C-alpha, in patients with advanced cancer. J. Clin. Oncol. 17: 3586–3595.

    Article  CAS  PubMed  Google Scholar 

  33. Flaherty KT, Stevenson JP, O’Dwyer PJ. (2001) Antisense therapeutics: lessons from early clinical trials. Curr. Opin. Oncol. 13: 499–505.

    Article  CAS  PubMed  Google Scholar 

  34. Huang L, Viroonchatapan E. (1999) Introduction. In Non-viral Vectors for Gene Therapy. 3–22, Academic Press, San Diego, CA.

    Chapter  Google Scholar 

  35. The Journal of Gene Medicine Clinical Trials Database. Available from: URL http://www.wiley.co.uk/wileychi/genmed/clinical. Accessed September 2001.

  36. NCI Clinical Trials Web Site. Available from: URL http://www.clinicaltrials.gov.

  37. Lian T, Ho RJ. (2001) Trends and developments in liposome drug delivery systems. J. Pharm. Sci. 90: 667–680.

    Article  CAS  PubMed  Google Scholar 

  38. Hughes J, Astriab A, Yoo H, et al. (2000) In vitro transport and delivery of antisense oligonucleotides. Meth. Enzymol. 313: 342–358.

    Article  CAS  PubMed  Google Scholar 

  39. Tari AM. (2000) Preparation and application of liposome-incorporated oligodeoxynucleotides. Meth. Enzymol. 313: 372–388.

    Article  CAS  PubMed  Google Scholar 

  40. Kondo Y, Koga S, Komata T, Kondo S. (2000) Treatment of prostate cancer in vitro and in vivo with 2-5A-anti-telom-erase RNA component. Oncogene 19: 2205–2211.

    Article  CAS  PubMed  Google Scholar 

  41. Mukai S, Kondo Y, Koga S, Komata T, Barna BP, Kondo S. (2000) 2-5A antisense telomerase RNA therapy for intracranial malignant gliomas. Cancer Res. 60: 4461–4467.

    PubMed  CAS  Google Scholar 

  42. Endo S, Zeng Q, Burke NA, et al. (2000) TGF-alpha antisense gene therapy inhibits head and neck squamous cell carcinoma growth in vivo. Gene Ther. 7: 1906–1914.

    Article  CAS  PubMed  Google Scholar 

  43. Gokhale PC, Soldatenkov V, Wang FH, et al. (1997) Antisense raf oligodeoxyribonucleotide is protected by liposomal encapsulation and inhibits Raf-1 protein expression in vitro and in vivo: implication for gene therapy of radioresistant cancer. Gene Ther. 4: 1289–1299.

    Article  CAS  PubMed  Google Scholar 

  44. Gokhale PC, McRae D, Monia BP, et al. (1999) Antisense raf oligodeoxyribonucleotide is a radiosensitizer in vivo. Antisense Nucleic Acid Drug Dev. 9: 191–201.

    Article  CAS  PubMed  Google Scholar 

  45. Yoo GH, Hung MC, Lopez-Berestein G, et al. (2001) Phase I trial of intratumoral liposome E1A gene therapy in patients with recurrent breast and head and neck cancer. Clin. Cancer Res. 7: 1237–1245.

    PubMed  CAS  Google Scholar 

  46. Hortobagyi GN, Ueno NT, Xia W, et al. (2001) Cationic liposome-mediated E1A gene transfer to human breast and ovarian cancer cells and its biological effects: a Phase I clinical trial. Clin. Pharmacol. 19: 3422–3433.

    CAS  Google Scholar 

  47. Wang S, Lee RJ, Cauchon G, Gorenstein DG, Low PS. (1995) Delivery of antisense oligodeoxyribonucleotides against the human epidermal growth factor receptor into cultured KB cells with liposomes conjugated to folate via polyethylene glycol. Proc. Natl. Acad. Sci. U.S.A. 92: 3318–3322.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  48. Tzahar E, Yarden Y. (1998) The ErbB-2/HER2 oncogenic receptor of adenocarcinomas: from orphanhood to multiple stromal ligands. [Review] [120 refs]. Biochim. Biophys. Acta 1377: M25–M37.

    PubMed  CAS  Google Scholar 

Download references

Acknowledgments

We thank Amy Marshall, Brianna Kalk, and Ekaterina Rait for their assistance in preparation of this manuscript; Ms. Wen-Hua Tang, and the Animal Research Shared Resources Facility for assistance with the animal studies. We also thank the Georgetown University Tissue Culture Core Facility and the Macromolecular Analysis Shared Resources Facility for their assistance. This work was supported in part by the National Foundation for Cancer Research Grant HU0001 (E. H. C.) and SynerGene Therapeutics, Inc. (K. F. P.).

Author information

Authors and Affiliations

  1. Department of Oncology, Lombardi Cancer Center, Georgetown University Medical Center, Research Building, E420, 3970 Reservoir Road NW, Washington, DC, 20057-1469, USA

    Antonina S. Rait, Kathleen F. Pirollo, Laiman Xiang, David Ulick & Esther H. Chang

Authors
  1. Antonina S. Rait
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kathleen F. Pirollo
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Laiman Xiang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. David Ulick
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Esther H. Chang
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Esther H. Chang.

Additional information

A. S. R. and K. F. P. contributed equally to this manuscript.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Rait, A.S., Pirollo, K.F., Xiang, L. et al. Tumor-targeting, Systemically Delivered Antisense HER-2 Chemosensitizes Human Breast Cancer Xenografts Irrespective of HER-2 Levels. Mol Med 8, 475–486 (2002). https://doi.org/10.1007/BF03402027

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03402027

Keywords

Search

Navigation